Keytruda (pembrolizumab) vs Columvi (glofitamab-gxbm)
Keytruda (pembrolizumab) vs Columvi (glofitamab-gxbm)
Keytruda (pembrolizumab) is an immune checkpoint inhibitor that works by blocking the PD-1 pathway, which enhances the body's immune response against cancer cells, and is commonly used for a variety of cancers including melanoma, lung cancer, and head and neck cancers. Cosela (trilaciclib) is a cyclin-dependent kinase inhibitor designed to protect bone marrow cells from damage caused by chemotherapy, and it is approved for use in patients with extensive-stage small cell lung cancer to decrease the incidence of chemotherapy-induced myelosuppression. When considering which medicine is right for an individual, it is crucial to consult with a healthcare provider to discuss the specific type of cancer, its stage, previous treatments, and the patient's overall health, as these factors significantly influence the choice of treatment.
Difference between Keytruda and Columvi
| Metric | Keytruda (pembrolizumab) | Columvi (glofitamab-gxbm) |
|---|---|---|
| Generic name | Pembrolizumab | Glofitamab-gxbm |
| Indications | Various types of cancers including melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and others | Currently being investigated for treatment of B-cell non-Hodgkin lymphoma |
| Mechanism of action | Programmed death receptor-1 (PD-1) blocking antibody | Bispecific CD20-directed CD3 T-cell engager |
| Brand names | Keytruda | Columvi |
| Administrative route | Intravenous infusion | Intravenous infusion |
| Side effects | Fatigue, musculoskeletal pain, decreased appetite, pruritus, diarrhea, nausea, rash, pyrexia, cough, dyspnea, constipation, pain in extremity, and headache | Not fully characterized yet as the drug is still in clinical trials, but may include cytokine release syndrome, neurologic toxicities, and infusion-related reactions |
| Contraindications | Individuals with hypersensitivity to pembrolizumab or any of its excipients | Not fully established yet as the drug is still in clinical trials |
| Drug class | Anti-PD-1 monoclonal antibody | Bispecific monoclonal antibody |
| Manufacturer | Merck & Co. | Genentech, a member of the Roche Group |
Efficacy
Keytruda (Pembrolizumab) Efficacy in Lymphoma
Keytruda, also known by its generic name pembrolizumab, is a monoclonal antibody that has been utilized in the treatment of various types of cancer, including lymphoma. It is a PD-1 (programmed death receptor-1) inhibitor that works by blocking a protective mechanism on cancer cells, which allows the immune system to destroy those cells. In the context of lymphoma, pembrolizumab has shown efficacy particularly in Hodgkin lymphoma after failure of other treatments. Clinical trials have demonstrated a significant proportion of patients achieving partial or complete remission, indicating its potential as a valuable therapeutic option for this patient population.
However, the efficacy of pembrolizumab can vary based on the subtype of lymphoma and previous treatments. It is most commonly used for patients with relapsed or refractory classical Hodgkin lymphoma. In these cases, studies have reported that pembrolizumab can induce durable responses with an acceptable safety profile. The drug has also been investigated in non-Hodgkin lymphoma, including primary mediastinal large B-cell lymphoma, with promising results in early-phase trials.
Columvi (Glofitamab-gxbm) Efficacy in Lymphoma
Columvi, known generically as glofitamab-gxbm, is an investigational bispecific antibody targeting CD20 on B-cells and CD3 on T-cells, designed to engage and activate the body's T-cells to attack B-cell lymphomas. While still in the clinical trial phase, glofitamab has shown promising efficacy in non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL), which is the most common type of non-Hodgkin lymphoma. In early clinical trials, patients with relapsed or refractory B-cell lymphomas have experienced significant response rates to glofitamab, with some achieving complete remission.
The efficacy of glofitamab is being evaluated across a range of B-cell lymphoma subtypes, and the results thus far suggest that it could become an important treatment option, particularly for those who have exhausted other therapies. As with all investigational drugs, the full profile of glofitamab's efficacy and safety will be better understood upon the completion of ongoing and future clinical trials. The potential for this drug to offer a new mechanism of action in the treatment of lymphoma is a subject of considerable interest in the oncology community.
Regulatory Agency Approvals
Keytruda
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
-
Medsafe (NZ)
Columvi
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Keytruda or Columvi today
If Keytruda or Columvi are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us